These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3700689)

  • 1. Pharmacokinetic and pharmacodynamic modeling of cibenzoline plasma concentrations and antiarrhythmic effect.
    Holazo AA; Brazzell RK; Colburn WA
    J Clin Pharmacol; 1986; 26(5):336-45. PubMed ID: 3700689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral cibenzoline in arrhythmia patients.
    Brazzell RK; Colburn WA; Aogaichi K; Szuna AJ; Somberg JC; Carliner N; Heger J; Morganroth J; Winkle RA; Block P
    Clin Pharmacokinet; 1985; 10(2):178-86. PubMed ID: 3995859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cibenzoline plasma concentration and antiarrhythmic effect.
    Brazzell RK; Aogaichi K; Heger JJ; Somberg JC; Carliner NH; Morganroth J
    Clin Pharmacol Ther; 1984 Mar; 35(3):307-16. PubMed ID: 6697638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral cibenzoline on steady-state digoxin concentrations in healthy volunteers.
    Khoo KC; Givens SV; Parsonnet M; Massarella JW
    J Clin Pharmacol; 1988 Jan; 28(1):29-35. PubMed ID: 3350991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemodynamic effects of a new antiarrhythmic agent: cibenzoline.
    Rigaud M; Jouret G; Canal M; Bardet J; Flouvat B; Bourdarias JP
    J Pharmacol; 1985; 16(3):247-57. PubMed ID: 4068726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration.
    Touboul P; Atallah G; Kirkorian G; de Zuloaga C; Dufour A; Aymard MF; Lavaud P; Moleur P
    Am Heart J; 1986 Aug; 112(2):333-9. PubMed ID: 3526853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiarrhythmic effects of cibenzoline.
    Miura DS; Keren G; Torres V; Butler B; Aogaichi K; Somberg JC
    Am Heart J; 1985 Apr; 109(4):827-33. PubMed ID: 3984837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cibenzoline for treatment of ventricular arrhythmias: a double-blind placebo-controlled study.
    Kostis JB; Krieger S; Moreyra A; Cosgrove N
    J Am Coll Cardiol; 1984 Aug; 4(2):372-7. PubMed ID: 6376595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term antiarrhythmic therapy with cibenzoline.
    Mohiuddin SM; Hilleman DE; Esterbrooks D; Mooss AN; Stengel LA
    J Clin Pharmacol; 1987; 27(5):400-6. PubMed ID: 3693585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cibenzoline. A review of its pharmacological properties and therapeutic potential in arrhythmias.
    Harron DW; Brogden RN; Faulds D; Fitton A
    Drugs; 1992 May; 43(5):734-59. PubMed ID: 1379150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiac electrophysiological effects of cibenzoline in the conscious dog: plasma concentration-response relationships.
    Boucher M; Dubray C; Kantelip JP; Talmant JM; Dufour A; Duchêne-Marullaz P
    J Cardiovasc Pharmacol; 1989 Oct; 14(4):616-21. PubMed ID: 2478775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response optimization of drug dosage: antiarrhythmic studies with tocainide.
    Meffin PJ; Winkle RA; Blaschke TF; Fitzgerald J; Harrison DC; Harapat SR; Bell PA
    Clin Pharmacol Ther; 1977 Jul; 22(1):42-57. PubMed ID: 872495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias.
    Hashimoto K; Akiyama K; Mitsuhashi H
    J Cardiovasc Pharmacol; 1987 Feb; 9(2):148-53. PubMed ID: 2435991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoglycemic effect of cibenzoline in patients with abnormal glucose tolerance and frequent ventricular arrhythmias.
    Saikawa T; Arita M; Yamaguchi K; Ito M
    Cardiovasc Drugs Ther; 2000 Dec; 14(6):665-9. PubMed ID: 11300368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias.
    Haruno A; Matsuzaki T; Hashimoto K
    J Cardiovasc Pharmacol; 1990 Sep; 16(3):376-82. PubMed ID: 1700207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiarrhythmic use of cibenzoline, a new class 1 antiarrhythmic agent with class 3 and 4 properties, in patients with recurrent ventricular tachycardia.
    Cocco G; Strozzi C; Pansini R; Rochat N; Bulgarelli R; Padula A; Sfrisi C; Kamal Al Yassini A
    Eur Heart J; 1984 Feb; 5(2):108-14. PubMed ID: 6723683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of oral cibenzoline and quinidine in ventricular arrhythmias: a randomized crossover study.
    Wasty N; Saksena S; Barr MJ
    Am Heart J; 1985 Dec; 110(6):1181-8. PubMed ID: 4072875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of oral cibenzoline for ventricular arrhythmias.
    Klein RC; Horwitz LD; Rushforth N
    Am J Cardiol; 1986 Mar; 57(8):592-7. PubMed ID: 3953445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cibenzoline for symptomatic ventricular arrhythmias: a prospective, randomized, double-blind, placebo controlled trial and a long term open label study.
    Lee MA; Fenster PE; Garcia ZM; Kipps JE; Huang SK
    Can J Cardiol; 1989 Sep; 5(6):295-8. PubMed ID: 2477130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coupling interval-related effects of class I antiarrhythmic drugs, mexiletine, cibenzoline and disopyramide, on ventricular activation in canine myocardial infarction.
    Hashimoto H; Satoh N; Nakashima M
    Jpn J Pharmacol; 1991 Dec; 57(4):463-72. PubMed ID: 1803064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.